

Special Issue

Antibiotic Use and Antibiotic Resistance in Dermatology

Message from the Guest Editors

Antimicrobial resistance is a global public health threat, and dermatologists encounter this phenomenon.

Topical and systemic antibiotics have been used in the management of dermatologic conditions for a long time, such as acne, rosacea, impetigo, hidradenitis suppurativa, and skin and soft tissue infections.

However, the overuse and misuse of antibiotics has led to the emergence of antibiotic-resistant bacteria, which can cause treatment failure, prolong the disease duration, and increase the healthcare costs. This Special Issue on "Antibiotic Use and Antibiotic Resistance in Dermatology" welcomes original research articles, reviews, and case reports that explore the problem of antibiotic resistance in dermatology and provide guidance on how to optimize antibiotic use in this field. The aim of this issue is to inform dermatologists, infectious disease specialists, and other healthcare professionals about the latest research on antibiotic use and resistance in dermatology.

Guest Editors

Dr. Ayman Grada

Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

Dr. Christopher Bunick

Department of Dermatology, Yale School of Medicine, New Haven, CT, USA

Deadline for manuscript submissions

31 August 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/175419

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)